Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt39....
-
Adoption de toutes les propositions du Conseil d’administration Réélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...
-
Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed39th...
-
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus...
-
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the...
-
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerabilityAt the maximally effective dose, there...
-
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with...
-
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus...
-
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED),...
-
MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous nephropathy progress to...